Objective: The aim of this study is to evaluate serum copper (Cu) and zinc (Zn) levels in patients with epithelial ovarian cancer and endometrioma. Materials and methods: We included 21 epithelial ovarian cancer patients, 47 endometrioma patients, 31 healthy women of reproductive age, and 10 healthy women in menopause. Cu and Zn levels and Cu/ Zn ratios were compared. Results: In the endometrioma group, Cu levels (P = 0.04) and Cu/ Zn ratio (P < 0.01) were higher, while Zn levels (P < 0.01) were lower compared to the control group. The threshold value of 1.15 with 62% sensitivity and 61% specificity was calculated for the Cu/ Zn ratio using the ROC curve (AUC = 0.688; P = 0.005). In the ovarian cancer group, Cu levels (P = 0.01) and Cu/ Zn ratio (P = 0.02) were higher, whereas Zn levels (P = 0.02) were lower compared to the control group. The Cu/ Zn ratio threshold value of 1.37 was calculated with 76% sensitivity and 90% specificity (AUC = 0.829; P = 0.004). The Zn level was lower (P = 0.02), and the Cu/ Zn ratio was higher (P = 0.01) in the ovarian cancer group compared to the endometrioma group. Conclusion: The threshold value of the Cu/ Zn ratio for ovarian cancer could be determined with a specificity of 90%, whereas the sensitivity and specificity of the Cu/ Zn ratio for endometrioma were low.
Background: To investigate whether intraovarian administration of quercetin-loaded extracellular vesicles derived from Wharton’s jelly mesenchymal stem cells (EVs-QUE) improves ovarian function in a cyclophosphamide (CTX)-induced premature ovarian insufficiency (POI) rat model. Methods: Human Wharton’s jelly-derived mesenchymal stem cells (MSCs) were cultured, and extracellular vesicles (EVs) were isolated and characterized by flow cytometry and electron microscopy. Quercetin was loaded onto EVs using ultrasonic incubation to generate EVs-QUE. A rat model of CTX-induced POI was established, and the subjects received intraovarian injections of either EVs or EVs-QUE. Ovarian function was assessed through histological evaluation, immunofluorescence staining, and gene expression analysis. Results: Treatment with EVs-QUE significantly improved ovarian morphology and folliculogenesis, reduced the number of atretic follicles, and decreased Casp3 expression. Proliferation markers ( Ki67 , Pcna ) and antioxidant genes ( Nrf2 , Sod1 ) were upregulated. Additionally, steroidogenesis- and oocyte-related genes ( Star , Gdf9 , Bmp15 ) showed increased expression. Although systemic hormonal alterations were limited, local tissue analysis confirmed a regenerative effect in the EVs-QUE group. Conclusions: Quercetin-loaded EVs derived from Wharton’s jelly MSCs enhanced ovarian recovery in a CTX-induced POI model through anti-apoptotic, pro-proliferative, and antioxidant pathways. These findings suggest that intraovarian administration of EVs-QUE may represent a promising strategy for fertility preservation and warrant further investigation in long-term and translational studies.
Alchemilla vulgaris has traditionally been used to treat gynecologic diseases. The anti-inflammatory and vasorelaxant effects of the extract of A. vulgaris (AVE) have been reported in previous studies. This study aimed to investigate the effects of A. vulgaris on PCOS, one of the most common metabolic disorders in adult women of reproductive age, accompanied by inflammation and vascular endothelial dysfunction, in an experimental animal model. Three groups of prepubertal female Wistar rats were established: PCOS, Control, and PCOS + AVE groups. Subcutaneous dehydroepiandrosterone (DHEA) was administered for 35 days to the PCOS and PCOS + AVE groups. The rats in the PCOS + AVE group were orally administered AVE (50 mg/100 g bw/day) for 35 days. Systemic blood pressure, vascular endothelial function, ovarian morphology, and endocrine biomarker levels were measured at the end of the experiment. TNF-α levels were also evaluated in the thoracic aorta and ovaries. Hormonal imbalances, ovarian morphological changes, and endothelial dysfunction were observed in the PCOS group, which returned to the controls after AVE treatment. Furthermore, AVE attenuated the aortic and ovarian levels of TNF-α in the PCOS group. Our study suggests that AVE may have beneficial effects in the treatment of PCOS due to its anti-inflammatory and vasculoprotective properties. Graphical Abstract